肾细胞癌治疗的最新进展。
Recent developments in the treatment of renal cell carcinoma.
机构信息
Associate Director, Cancer Research Foundation, Immediate Past Chair of ECOG-ACRIN Renal Cancer Subcommittee, 750 Kappock Street, # 511, Bronx, NY 10463, USA.
出版信息
Ther Adv Urol. 2013 Dec;5(6):338-53. doi: 10.1177/1756287213505672.
Abstract
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the understanding of the molecular characterizations of subtypes of RCC with potential to lead to new therapeutic options. Additionally, the urologic oncology community is focusing on nephron-sparing surgical approaches with limited surgery if possible, and in conjunction with interventional radiologists, on ablative procedures for incidentally determined small renal masses. This report reviews some of the new biologic findings of adenocarcinoma of the kidney, and reviews the new therapeutics which continue to change the landscape for treatment of RCC.
摘要
肾细胞癌（RCC）的治疗一直备受关注，这在很大程度上是由于最近在晚期和转移性疾病的新治疗选择方面取得了成功。与此同时，人们对 RCC 亚型的分子特征的理解也取得了一些不太广为人知的进展，这有可能为新的治疗选择提供依据。此外，泌尿科肿瘤学领域的研究人员正在关注保留肾单位的手术方法，如果可能的话，尽量减少手术，并与介入放射科医生合作，对偶然发现的小肾肿瘤进行消融治疗。本报告回顾了肾腺癌的一些新的生物学发现，并回顾了不断改变 RCC 治疗格局的新疗法。
相似文献
1
Recent developments in the treatment of renal cell carcinoma.
Ther Adv Urol. 2013 Dec;5(6):338-53. doi: 10.1177/1756287213505672.
2
Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review.
Med Oncol. 2023 Nov 13;40(12):355. doi: 10.1007/s12032-023-02225-0.
3
Evaluation and management of the renal mass.
Med Clin North Am. 2011 Jan;95(1):179-89. doi: 10.1016/j.mcna.2010.08.021.
4
Current management of renal cell carcinoma and targeted therapy.
Urol J. 2006 Winter;3(1):1-14.
5
Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Dan Med J. 2017 Oct;64(10).
6
Novel approaches in the therapy of metastatic renal cell carcinoma.
World J Urol. 2005 Jul;23(3):202-12. doi: 10.1007/s00345-004-0466-0. Epub 2005 Apr 5.
7
Surgical management of renal cell carcinoma.
Semin Oncol. 2006 Oct;33(5):552-62. doi: 10.1053/j.seminoncol.2006.06.007.
8
Changing concepts in the surgical management of renal cell carcinoma.
Eur Urol. 2004 Jun;45(6):692-705. doi: 10.1016/j.eururo.2004.02.002.
9
Nephron sparing surgery for renal tumors: indications, techniques and outcomes.
J Urol. 2001 Jul;166(1):6-18.
10
Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy.
Tumori. 2017 Jan 21;103(1):15-21. doi: 10.5301/tj.5000581. Epub 2016 Oct 26.
引用本文的文献
1
NUTM2A-AS1 as a potential key regulator in cancer: unraveling its ceRNA networks and impact on tumor biology.
Eur J Med Res. 2025 Sep 3;30(1):840. doi: 10.1186/s40001-025-03019-y.
2
The relationship between preoperative serum cystatin C levels and postoperative oncologic outcomes in patients with renal cell carcinoma: a systematic review and meta-analysis of 1641 patients.
Updates Surg. 2025 May 6. doi: 10.1007/s13304-025-02208-y.
3
DNA vaccines as promising immuno-therapeutics against cancer: a new insight.
Front Immunol. 2025 Jan 13;15:1498431. doi: 10.3389/fimmu.2024.1498431. eCollection 2024.
4
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Mol Cancer. 2024 Mar 16;23(1):56. doi: 10.1186/s12943-024-01952-w.
5
Evolution of cell therapy for renal cell carcinoma.
Mol Cancer. 2024 Jan 9;23(1):8. doi: 10.1186/s12943-023-01911-x.
6
A Cuproptosis-Related Gene Model For Predicting the Prognosis of Clear Cell Renal Cell Carcinoma.
Front Genet. 2022 Aug 11;13:905518. doi: 10.3389/fgene.2022.905518. eCollection 2022.
7
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Front Immunol. 2021 Oct 27;12:778459. doi: 10.3389/fimmu.2021.778459. eCollection 2021.
8
Effect of Aberrant Long Noncoding RNA on the Prognosis of Clear Cell Renal Cell Carcinoma.
Comput Math Methods Med. 2021 Sep 3;2021:6533049. doi: 10.1155/2021/6533049. eCollection 2021.
9
miR-129-5p inhibits clear cell renal cell carcinoma cell proliferation, migration and invasion by targeting SPN.
Cancer Cell Int. 2021 May 17;21(1):263. doi: 10.1186/s12935-021-01820-3.
10
Biological Evaluation of Oxindole Derivative as a Novel Anticancer Agent against Human Kidney Carcinoma Cells.
Biomolecules. 2020 Aug 31;10(9):1260. doi: 10.3390/biom10091260.
本文引用的文献
1
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15.
2
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ann Oncol. 2015 Jul;26(7):1378-84. doi: 10.1093/annonc/mdv170. Epub 2015 Apr 7.
3
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
J Clin Oncol. 2014 Mar 10;32(8):752-9. doi: 10.1200/JCO.2013.50.5305. Epub 2013 Dec 2.
4
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9.
5
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
6
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16.
7
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Br J Cancer. 2013 Apr 16;108(7):1393-401. doi: 10.1038/bjc.2013.96. Epub 2013 Mar 19.
8
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901.
Oncoimmunology. 2013 Jan 1;2(1):e22246. doi: 10.4161/onci.22246.
9
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12.
10
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063.
Zotero 插件